American Society for Transplantation and Cellular Therapy Series: #4 - Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation Guidelines


Authors: Yong, M. K.; Shigle, T. L.; Kim, Y. J.; Carpenter, P. A.; Chemaly, R. F.; Papanicolaou, G. A.
Title: American Society for Transplantation and Cellular Therapy Series: #4 - Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation
Abstract: The Practice Guidelines Committee of the American Society of Transplantation and Cellular Therapy (ASTCT) partnered with its Transpl. Infect. Dis. Special Interest Group (TID-SIG) to update its 2009 compendium-style infectious disease guidelines for hematopoietic cell transplantation (HCT). A new approach was employed with the goal of better serving clinical providers by publishing each standalone topic in the infectious diseases series as a concise format of frequently asked questions (FAQ), tables, and figures. Adult and pediatric infectious diseases and HCT content experts developed and answered FAQs. Topics were finalized with harmonized recommendations that were made by assigning an A through E strength of recommendation paired with a level of supporting evidence graded I through III. The fourth topic in the series focuses on the management and treatment of cytomegalovirus (CMV) resistant and refractory infections. The diagnosis, definitions of resistant and refractory CMV, risk factors, virological genotypes and treatment algorithms are reviewed. © 2021
Journal Title: Transplantation and Cellular Therapy
Volume: 27
Issue: 12
ISSN: 2666-6375
Publisher: Elsevier Inc.  
Date Published: 2021-12-01
Start Page: 957
End Page: 967
Language: English
DOI: 10.1016/j.jtct.2021.09.010
PUBMED: 34560310
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 3 January 2022 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors